FDA Peptide Compounding: The Ban, the 12 Under Review, and What It Means
Redaktion
Forschungsbereich
Die Zusammenfassungsblöcke und der vollständige Artikel sind aus redaktionellen Gründen auf Englisch. Titel, Beschreibung und dieses Intro sind lokalisiert.
FDA Peptide Compounding: The Ban, the 12 Under Review, and What It Means
Breaking: April 15, 2026 — 12 Peptides Removed from the Ban for Expert Review
On April 15, 2026, the FDA announced it would remove 12 peptides from Category 2 — the "significant safety concerns" list that banned them from compounding pharmacies since late 2024 — and send them to the Pharmacy Compounding Advisory Committee (PCAC) for deeper expert review.
This is not approval. It is the FDA stepping back to let a specialist panel weigh clinical need and safety data before making a final call. But it is a meaningful softening — these peptides are no longer categorically dismissed.
The 12 peptides under PCAC review:
| Peptide | PCAC Meeting |
|---|---|
| BPC-157 | July 23, 2026 |
| TB-500 | July 23, 2026 |
| KPV | July 23, 2026 |
| MOTS-c | July 23, 2026 |
| Emideltide (DSIP) | July 24, 2026 |
| Semax | July 24, 2026 |
| Epitalon | July 24, 2026 |
| Cathelicidin LL-37 | By Feb 2027 |
| Dihexa | By Feb 2027 |
| GHK-Cu | By Feb 2027 |
| PEG-MGF | By Feb 2027 |
| Melanotan II | By Feb 2027 |
Public comments are open through July 22, 2026 (FDA docket FDA-2025-N-6895).
The 2024 Ban: What Happened
In late 2024, the FDA finalized its decision to add a significant number of peptide compounds to the Category 2 Bulk Drug Substances list — effectively prohibiting licensed US compounding pharmacies from producing or dispensing them. This is the most significant regulatory shift in the US peptide research and wellness space in years.
What "Category 2" Means
US compounding law allows pharmacies to compound drugs from bulk drug substances — but only from substances on an approved list (Category 1). Category 2 is where the FDA places substances it has evaluated and determined lack a clinical need that would justify compounding, or where there are safety or regulatory concerns.
Being placed on Category 2 does not make a peptide illegal to possess as an individual, but it removes the primary legitimate domestic supply channel — licensed compounding pharmacies that operate under state board and federal oversight.
Peptides Affected by the Ban
The FDA's 2024 action included, but is not limited to:
| Peptide | Common Use Context |
|---|---|
| BPC-157 | Tissue repair, gut health, injury recovery |
| Epitalon | Longevity, telomerase, sleep |
| Thymosin Alpha-1 (TA-1) | Immune modulation, antiviral |
| Thymosin Beta-4 / TB-500 | Recovery, tissue repair |
| MOTS-c | Mitochondrial, metabolic, exercise mimicry |
| GHK-Cu | Skin repair, wound healing, cosmetic |
| KPV | Anti-inflammatory, gut |
| Selank | Nootropic, anxiolytic |
| Semax | Nootropic, neuroprotection |
| PT-141 (Bremelanotide) | Sexual function (note: Vyleesi is FDA-approved) |
| Ipamorelin | GH secretagogue |
| CJC-1295 | GHRH analog, GH pulse |
| Hexarelin | GH secretagogue |
| Sermorelin | GHRH analog |
| Tesamorelin | GH-releasing (note: Egrifta is FDA-approved for HIV lipodystrophy) |
Note: This list reflects publicly available information as of early 2026. Confirm current status with regulatory sources, as legal challenges may affect enforcement.
What Changed in Practice
Before the ban: Patients in the US could obtain prescriptions for many of these peptides from licensed compounding pharmacies that sourced pharmaceutical-grade bulk material.
After the ban: That supply chain is no longer available through licensed US compounders. Researchers and patients seeking these compounds now face:
- Research-grade gray-market sources with variable quality and no pharmacy oversight.
- International sources with their own regulatory complexities.
- Clinical trial access for compounds with active trials (limited by eligibility).
Legal Challenges and Ongoing Uncertainty
The ban has been met with active legal challenges from compounding pharmacy associations and patient advocacy groups, arguing the FDA's clinical-need determinations were insufficiently supported. As of mid-2026:
- Some challenges are unresolved in federal courts.
- Enforcement may vary by compound and supply chain context.
- The regulatory landscape is not fully settled.
Researchers should verify current status for any specific compound rather than treating the 2024 list as final.
What This Means for Evidence and Access
The compounding ban has a secondary effect on evidence generation: if licensed US facilities cannot produce these compounds, running US-based clinical trials becomes harder, reinforcing the existing evidence gap for many of these peptides. This is a systemic concern for the field, not just a consumer-access question.
Key Distinctions: Banned from Compounding ≠ Illegal
- Banned from compounding: Compounding pharmacies cannot make or dispense the compound.
- Research-grade supply: Still exists through research chemical suppliers — separate regulatory category with its own risks (no pharmacy oversight, variable purity).
- Individual possession: Generally not criminalized in the US for research peptides, though this varies by compound (some have DEA scheduling implications independently).
- FDA-approved versions: Where an FDA-approved drug exists (e.g., Vyleesi for PT-141, Egrifta for tesamorelin), those remain available via standard prescription channels.
Bottom Line
The 2024 FDA compounding ban materially changed the US peptide access landscape. Understanding what changed — and what it did not change — is essential context for any researcher following these compounds. Legal uncertainty remains; the landscape will continue to evolve.
Educational content only. Not medical advice. Verify current regulatory status in your jurisdiction.
FAQ — Antworten zuerst
Kurze Fragen und Antworten für Lesbarkeit und Suchmaschinen.
Is BPC-157 illegal in the US after the ban?
Not illegal to possess, but BPC-157 is now prohibited from US compounding pharmacies under the FDA Category 2 ruling. This removes the primary legitimate domestic supply channel. Research-grade sources remain available under a different regulatory framework, with associated quality and legal uncertainties.
Which peptides did the FDA ban from compounding?
The 2024 action included BPC-157, epitalon, thymosin alpha-1, thymosin beta-4 (TB-500), MOTS-c, GHK-Cu, KPV, selank, semax, PT-141, ipamorelin, CJC-1295, hexarelin, sermorelin, and tesamorelin, among others. The list applies to compounding pharmacies, not individual possession.
Are there legal challenges to the peptide compounding ban?
Yes. Compounding pharmacy associations and patient groups have filed legal challenges arguing the FDA's clinical-need determinations were inadequately supported. As of mid-2026, some challenges remain active in federal courts, meaning the regulatory situation is not fully settled.
Can I still access these peptides through an FDA-approved product?
For some compounds, yes. PT-141 has an FDA-approved form (Vyleesi for hypoactive sexual desire disorder). Tesamorelin has an approved form (Egrifta for HIV-associated lipodystrophy). For most others on the ban list, no FDA-approved formulation exists, meaning the compounding channel was the primary access route.
Weiter entdecken
Forschungspeptide mit Fremdtests und Analysezertifikat.
Shop Peptides